1. [Results of radical removal of malignant cerebral gliomas, by using computer-assisted navigation, followed by adjuvant therapy].
- Author
-
Krivoshapkin AL, Kanygin VV, Semin PA, and Melidi EG
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Brain Neoplasms diagnostic imaging, Brain Neoplasms drug therapy, Chemotherapy, Adjuvant, Cohort Studies, Combined Modality Therapy, Dacarbazine administration & dosage, Dacarbazine analogs & derivatives, Dacarbazine therapeutic use, Drug Administration Schedule, Female, Glioma drug therapy, Glioma radiotherapy, Humans, Karnofsky Performance Status, Male, Middle Aged, Nitrosourea Compounds administration & dosage, Nitrosourea Compounds therapeutic use, Organophosphorus Compounds administration & dosage, Organophosphorus Compounds therapeutic use, Radiography, Retrospective Studies, Stereotaxic Techniques, Temozolomide, Treatment Outcome, Antineoplastic Agents therapeutic use, Brain Neoplasms surgery, Glioma surgery, Neurosurgical Procedures methods, Surgery, Computer-Assisted
- Abstract
A retrospective cohort analysis of the results of treatment of patients with malignant gliomas was made in 2 groups, each comprising 43 patients. In Group 1, the tumors were radically removed under neuronavigation guidance ("Voyager SX"). In Group 2 where the patients were operated on by the same team of surgeons who did not employ computer-assisted navigation technologies. The results of different adjuvant therapy regimens were analyzed in patients after radical tumor removal under navigation guidance (Group 1). In its first subgroup, 24 patients with anaplastic astrocytes were postoperatively irradiated (60 Gy), followed by treatment with temodal (200 mg/m2 (mean 6 courses). In the second subgroup, 12 patients received chemoradiotherapy (temodal, 75 mg/m2 daily + irradiation), followed by courses (n=6) of temodal, 200 mg/m2). In the third subgroup, 7 patients were treated with fotemustin (200 mg/m2 (induction) + 5 cycles). The computer-assisted technologies substantially improve a postoperative outcome in patients with malignant glionas. Current chemoradiotherapy is relatively safe and prolongs a relapse-free interval with a high quality of life. Further studies call for the efficiency of different adjuvant therapy regimens after radical surgery.
- Published
- 2006